USCOM LIMITED — Capital/Financing Update 2014

Jan 28, 2014

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

M A R K E T A N N O U N C E M E N T

Uscom appoints Deltex to distribution team

Wednesday 29th of January 2014: Uscom (ASX code: UCM)

Uscom Limited today announced execution of a three year distribution and market collaboration agreement with Deltex Medical Group PLC (AIM code: DMEG), UK. The agreement appoints Deltex as a nonexclusive distributor for the USCOM 1A, and establishes the foundations for further collaboration in the delivery of Doppler technologies to the global cardiovascular monitoring market.

Deltex manufactures and markets the CardioQ-ODM Oesophageal Doppler Monitor (ODM) and has excellent representation in the UK NHS system, as a leading proponent and adopter of Doppler haemodynamic monitoring. The ODM is marketed for peri-operative and intra-operative surgical monitoring with the Deltex business model based on sales of single patient disposable probes. The USCOM 1A is noninvasive with widespread application in sepsis, heart failure and hypertension in neonates, children, adults and the elderly and is marketed as a single capital sale. The devices are complementary and have practice leading clinical evidence, and both companies are committed to growing the cardiac output monitoring market aggressively, by expansion into routine clinical practice in addition to replacement of invasive and less accurate technologies with safe and accurate Doppler ultrasound technologies.

Deltex has 24 direct sales staff and educators in the sophisticated UK market, and a further 10 in the US. Deltex also has channels into Europe, Eastern Europe, the Middle East and Africa. It is planned that USCOM will be introduced into the additional Deltex distribution channels, and the ODM will be introduced into current Uscom distribution channels over the next twelve months. This partnership represents a collaboration between the two major Doppler cardiac monitoring companies to better exploit growing market opportunities, and is in response to the increasing recognition by clinicians of the clinical importance of Doppler cardiac monitoring. The best endeavours agreement is targeted to generate $582k AUD revenue to Uscom in year one.

Executive Chairman of Uscom, Rob Phillips said, “This Doppler partnership shifts the cardiac monitoring landscape. Doppler is now a clear lead technology in the sophisticated cardiovascular monitoring market, and Uscom and Deltex lead this field. Deltex have excellent sales, education and clinical support channels, particularly into the UK market and this partnership delivers USCOM into these new global sales and distribution channels. This partnership will generate immediate revenue for both companies, provide for market growth and market consolidation, and establish a foundation for longer term strategic opportunities.”

Deltex’s CEO, Ewan Phillips said, “Uscom and Deltex have identified opportunities to sell their complimentary technologies into their existing customer bases. The partnership expands the breadth of each company’s clinical offer and allows both companies to further differentiate the strengths of Doppler ultrasound haemodynamic monitoring and measurement.”

The USCOM 1A and ODM technologies are complementary and used to simplify and improve cardiovascular diagnosis, management and monitoring in different clinical environments.

References: http://www.deltexmedical.com

National Health Scheme Technology Adoption Centre. Intraoperative Fluid Management Technologies Adoption Pack. 2012 http://www.ntac.nhs.uk/.

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

M A R K E T A N N O U N C E M E N T

About Uscom

Uscom Limited is an ASX listed cardiovascular medical device company (UCM). Uscom is an innovative developer and manufacturer of premium cardiovascular devices and has two practice leading technologies in the field of cardiovascular monitoring, the USCOM 1A and the BP+. The devices are both clinically validated with FDA, CE and TGA regulatory approval, and are currently being marketed into global distribution networks.

The USCOM 1A is a simple, cost-effective and non-invasive device that measures heart function, detects irregularities and guides treatment. The USCOM device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anesthesia, and is the device of choice for management of adult and paediatric sepsis, and for the guidance of fluid therapy.

The Uscom BP+ is a supra systolic Central Blood Pressure monitor and replaces older and more widespread BP sub systolic Blood Pressure monitoring technology. Central Bood Pressure is becoming the new standard of care measurement in hypertension and heart failure. The Uscom BP+ provides a highly accurate & repeatable measurements of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in cardiology, intensive care, general practice and home care.

For more information, please visit: http://www.uscom.com.au.

Uscom Contacts Rob Phillips Executive Chairman rob@uscom.com.au

Catherine Officer Company Secretary secretary@uscom.com.au